Profile data is unavailable for this security.
About the company
Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
- Revenue in USD (TTM)40.93m
- Net income in USD-16.25m
- Incorporated2013
- Employees46.00
- LocationPieris Pharmaceuticals Inc225 Franklin Street, 26Th FloorBOSTON 02110United StatesUSA
- Phone+1 (857) 246-8998
- Fax+49 (8161) 141-1444
- Websitehttps://www.pieris.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Calidi Biotherapeutics Inc | 0.00 | -29.98m | 10.10m | 41.00 | -- | -- | -- | -- | -0.6765 | -0.6765 | 0.00 | -0.4079 | 0.00 | -- | -- | 0.00 | -382.78 | -- | -- | -- | -- | -- | -- | -- | -- | -27.45 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
Eterna Therapeutics Inc | 115.00k | -22.92m | 10.14m | 8.00 | -- | -- | -- | 88.20 | -4.25 | -4.25 | 0.0214 | -0.6307 | 0.0036 | -- | 0.2305 | 14,375.00 | -70.71 | -169.05 | -88.77 | -223.00 | -114.78 | -- | -19,912.17 | -682.61 | -- | -15.55 | 1.64 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
Alaunos Therapeutics Inc | 6.00k | -26.77m | 10.39m | 1.00 | -- | 2.17 | -- | 1,732.02 | -1.67 | -1.67 | 0.0004 | 0.2996 | 0.0002 | -- | 12.00 | 6,000.00 | -97.94 | -74.83 | -147.22 | -89.57 | -- | -- | -446,233.30 | -10,508.06 | -- | -19.25 | 0.00 | -- | -99.83 | -49.08 | 6.86 | -- | -15.56 | -- |
Vaccinex Inc | 124.00k | -19.19m | 10.52m | 37.00 | -- | 7.41 | -- | 84.84 | -46.02 | -46.02 | 0.1685 | 1.68 | 0.0202 | -- | 0.0894 | 3,351.35 | -312.93 | -262.29 | -731.45 | -- | -- | -- | -15,472.58 | -4,257.17 | -- | -55.90 | 0.03 | -- | 107.27 | -4.67 | -2.20 | -- | -22.20 | -- |
Organovo Holdings Inc | 109.00k | -14.67m | 10.82m | 12.00 | -- | 2.11 | -- | 99.28 | -1.62 | -1.62 | 0.0119 | 0.3573 | 0.0082 | -- | 1.18 | 5,450.00 | -110.05 | -54.25 | -138.86 | -58.42 | -- | -- | -13,459.63 | -1,890.16 | 1.96 | -- | 0.00 | -- | -70.54 | -48.78 | 15.00 | -- | -11.87 | -- |
ELEVAI Labs Inc | 2.18m | -4.62m | 10.86m | 18.00 | -- | 4.01 | -- | 4.97 | -0.2665 | -0.2665 | 0.126 | 0.1435 | -- | -- | -- | 121,351.70 | -- | -- | -- | -- | 67.84 | -- | -211.42 | -- | 1.80 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
Longeveron Inc | 978.00k | -21.62m | 10.98m | 23.00 | -- | 1.43 | -- | 11.23 | -9.58 | -9.58 | 0.4297 | 1.21 | 0.0621 | -- | 7.14 | 42,521.74 | -132.19 | -63.15 | -184.16 | -75.68 | 48.47 | 33.70 | -2,129.24 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
Pieris Pharmaceuticals Inc | 40.93m | -16.25m | 11.09m | 46.00 | -- | 0.473 | -- | 0.271 | -12.74 | -12.74 | 34.05 | 17.76 | 0.7324 | -- | 28.25 | 889,717.40 | -29.09 | -28.41 | -52.98 | -39.69 | -- | -- | -39.71 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
Dominari Holdings Inc | 3.41m | -24.56m | 11.16m | 26.00 | -- | 0.2341 | -- | 3.28 | -4.64 | -4.64 | 0.6305 | 8.03 | 0.0539 | -- | 0.8023 | 131,000.00 | -38.88 | -26.82 | -39.93 | -27.45 | -- | -- | -721.11 | -3,353.52 | -- | -- | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
Check Cap Ltd | 0.00 | -17.57m | 11.76m | 85.00 | -- | 0.4965 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
Oncotelic Therapeutics Inc | 70.00k | -7.79m | 11.99m | 22.00 | -- | 1.01 | -- | 171.29 | -0.0197 | -0.0197 | 0.0002 | 0.0296 | 0.0021 | -- | 3.61 | 3,181.82 | -24.46 | -25.03 | -49.25 | -48.76 | -- | -- | -11,536.00 | -1,692.93 | -- | -0.4696 | 0.5341 | -- | -- | -- | -255.12 | -- | -- | -- |
Enzon Pharmaceuticals Inc | 0.00 | 221.00k | 12.03m | 0.00 | 54.38 | 3.65 | -- | -- | 0.003 | 0.003 | 0.00 | 0.624 | 0.00 | -- | -- | -- | 3.21 | -0.8654 | 3.24 | -0.8851 | -- | -- | -- | -159.43 | -- | -- | 0.00 | -- | -100.00 | -- | 106.71 | -55.86 | -- | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 15 May 2024 | 257.62k | 19.51% |
Lynx1 Capital Management LPas of 31 Mar 2024 | 109.74k | 8.31% |
Renaissance Technologies LLCas of 31 Mar 2024 | 17.87k | 1.35% |
Hudson Valley Investment Advisors, Inc.as of 30 Jun 2024 | 14.00k | 1.06% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 12.94k | 0.98% |
Acadian Asset Management LLCas of 31 Mar 2024 | 12.03k | 0.91% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 11.07k | 0.84% |
Citadel Advisors LLCas of 31 Mar 2024 | 9.84k | 0.75% |
Geode Capital Management LLCas of 31 Mar 2024 | 9.66k | 0.73% |
CM Management LLCas of 31 Mar 2024 | 7.19k | 0.54% |